Crizanlizumab Production Cost Reports

The report provides a detailed analysis essential for establishing a crizanlizumab production plant. It encompasses all critical aspects necessary for crizanlizumab production, including the cost of crizanlizumab production, crizanlizumab plant cost, crizanlizumab production costs, and the overall crizanlizumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a crizanlizumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Crizanlizumab, marketed as Adakveo, is a humanised monoclonal antibody developed by Novartis for medical applications in treating sickle cell disease. It targets P-selectin to inhibit red blood cell adhesion to vascular endothelium, which reduces the frequency of vaso-occlusive crises in patients aged 16 and older. It was approved by the FDA in 2019 and administered via intravenous infusion. It showed clinical efficacy in trials like SUSTAIN, achieving up to 45% fewer pain crises when used along with standard therapies such as hydroxyurea, with ongoing research exploring its potential in related inflammatory conditions.

Crizanlizumab’s market growth is driven by the rising global prevalence of sickle cell disease, mainly in developing regions like sub-Saharan Africa and parts of Asia, where untreated cases fuel demand for targeted therapies that reduce vaso-occlusive crises. The increasing adoption by healthcare providers and technological advancements in monoclonal antibody production boost the market growth. Additionally, supportive government reimbursement policies in key markets such as North America, which dominates due to high disease incidence and an established biopharma infrastructure fuels the market expansion.

Moreover, opportunities in untapped emerging markets and potential personalised medicine applications also contribute to the market demand. However, challenges like high treatment costs, limited awareness in some areas, and regulatory setbacks influence industrial crizanlizumab procurement. Furthermore, supply chain logistics for cold-chain storage and IV administration, vial wastage impacting budgeting, payer negotiations for orphan drug status flexibility, and clinical eligibility tied to high-risk patients unresponsive to hydroxyurea, impact the overall procurement.

Raw Material for Crizanlizumab Production

According to the crizanlizumab production plant project report, the various raw materials for crizanlizumab production include Chinese hamster ovary cell lines.

Production Process of Crizanlizumab

The extensive crizanlizumab production cost report consists of the following major industrial production process:

1. Production via a controlled fed-batch bioreactor process: The production process of crizanlizumab occurs through recombinant DNA technology in a stably transfected Chinese hamster ovary (CHO) cell line using a controlled fed-batch bioreactor process. In this process, a single vial from the working cell bank is thawed, expanded, and scaled up to production scale for multi-batch harvesting of cell culture fluid. The harvest undergoes multi-step purification, starting with protein A affinity chromatography for capture, followed by polishing via ion-exchange or hydrophobic interaction chromatography. The final step includes two orthogonal viral inactivation/removal processes (such as low pH incubation and detergent treatment or nanofiltration), resulting in final diafiltration/ultrafiltration for buffer exchange into the formulated bulk.

Properties of Crizanlizumab

Crizanlizumab (Adakveo), a humanised IgG2 monoclonal antibody with a molecular weight of 146 kDa (C6458H9948N1712O2050S58, 146,232 g/mol), targets P-selectin to prevent vaso-occlusive crises in sickle cell disease patients aged 16+. It possesses various properties, such as a 10 mg/mL sterile solution (pH 6, osmolality ~300 mOsm/kg) with excipients including sodium citrate, sucrose, and polysorbate 80, requiring cold-chain storage and visual clarity checks. It is chemically stable for IV infusion post-dilution and shows pharmacokinetics such as Cmax 0.16 mg/mL and Tmax ~1.92 hours at 5 mg/kg, produced recombinantly in CHO cells.